Legal & General Group’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.13M Sell
81,243
-17,232
-17% -$636K ﹤0.01% 1728
2025
Q4
$3.5M Sell
98,475
-339
-0.3% -$9.53K ﹤0.01% 1756
2025
Q3
$1.42M Buy
98,814
+18,769
+23% +$222K ﹤0.01% 2121
2025
Q2
$575K Buy
80,045
+10,878
+16% +$60.3K ﹤0.01% 2404
2025
Q1
$414K Sell
69,167
-374
-0.5% -$2.93K ﹤0.01% 2453
2024
Q4
$542K Buy
69,541
+1,911
+3% +$19K ﹤0.01% 2432
2024
Q3
$730K Buy
67,630
+330
+0.5% +$3.21K ﹤0.01% 2343
2024
Q2
$567K Buy
67,300
+13,182
+24% +$100K ﹤0.01% 2381
2024
Q1
$364K Sell
54,118
-700
-1% -$4.33K ﹤0.01% 2546
2023
Q4
$322K Buy
54,818
+449
+0.8% +$3.44K ﹤0.01% 2606
2023
Q3
$530K Buy
54,369
+439
+0.8% +$5.21K ﹤0.01% 2412
2023
Q2
$639K Buy
53,930
+38,383
+247% +$440K ﹤0.01% 2376
2023
Q1
$168K Buy
15,547
+1,128
+8% +$14.4K ﹤0.01% 2646
2022
Q4
$167K Buy
14,419
+8,449
+142% +$105K ﹤0.01% 2682
2022
Q3
$89K Buy
5,970
+2,203
+58% +$30.2K ﹤0.01% 2856
2022
Q2
$34K Buy
3,767
+529
+16% +$3.61K ﹤0.01% 3081
2022
Q1
$24K Hold
3,238
﹤0.01% 3183
2021
Q4
$28K Hold
3,238
﹤0.01% 3170
2021
Q3
$27K Hold
3,238
﹤0.01% 3159
2021
Q2
$26K Buy
+3,238
New +$27.3K ﹤0.01% 3189
2019
Q3
Sell
-741
Closed -$8K 3363
2019
Q2
$8K Hold
741
﹤0.01% 3390
2019
Q1
$13K Hold
741
﹤0.01% 3202
2018
Q4
$13K Buy
741
+554
+296% +$16.4K ﹤0.01% 3213
2018
Q3
$8K Hold
187
﹤0.01% 3340
2018
Q2
$11K Buy
+187
New +$8.99K ﹤0.01% 3289

Other funds holding COGT

Legal & General Group's COGT Position: Q1 2026 in Review

Legal & General Group reduced its Cogent Biosciences (COGT) stake by 17% in Q1 2026, selling an estimated $636K and leaving 81,243 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Legal & General Group first reported a position in COGT in Q2 2018 and has held it in 25 quarters since. The position peaked at $3.5M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Legal & General Group held 81,243 shares of Cogent Biosciences worth $3.13M as of Q1 2026.
  • Legal & General Group sold 17,232 Cogent Biosciences shares in Q1 2026, an estimated $636K.
  • Cogent Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1728 holding.
  • Legal & General Group first reported a position in Cogent Biosciences in Q2 2018 and has held it in 25 quarters since.
  • Legal & General Group's Cogent Biosciences position peaked at $3.5M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.